The Clinical Evaluation In The Treatment Of Primary Liver Cancer By The Decoction Of Supplementing Liver And Spleen Combined With TACE And 3-DCRT

Objective:The clinical efficacy in the treatment of primary hepatocellular carcinoma with the decoction of supplementing Liver and spleen combined with TACE and 3-DCRT, to evaluate its advantages and disadvantages in improving patient syndromes, tumor size, cellular immune function, liver function, quality of life, survival rate and other aspects of clinical efficacy.Methods:The clinical choice conforms to 51 patients with primary hepatocellular carcinoma patients with the inclusion criteria, randomly divided into two groups, the treatment group (26 cases) given medicine combined with TACE and 3-DCRT treatment and control group (25 cases) treated with TACE and 3-DCRT treatment, the two groups were observed before and after treatment in syndromes, tumor size, cellular immune function, liver function, quality of life, survival rate and other aspects of Related indicators and statistical analysis.Results:The rapeutic effect of the treatment group, the total efficiency of 88.0%, there was significant difference compared with the control group (P<0.05), treatment group waiting on total credit improvement than the control group (P<0.05), especially on the "hypochondriac ""abdominal nausea "," lassitude "," eat less "," bloating "," mouth stick not want to drink, "and other symptoms have significant improvement (P<0.05), but on the"lump ", " fever "no significant improvement (P>0.05);the treatment group and control group comparison of the immunity cells, CD3+, CD3+CD4+changes were significant differences (P<0.05), and CD3+CD8+was no significant difference (P>0.05); the treatment group and control group in contrast to improve liver function, In terms of reducing ALT, AST indicators, there are significant differences (P<0.05), no significant difference in TBIL aspect; The treatment and control groups in terms of improving quality of life scores compared the treatment group than the control group (P<0.05);In terms of tumor size and the survival rate,the treatment group was higher than the control group, but the difference was not statistically significant between them (P>0.05).Conclusion:the method which was treating primary hepatocellular carcinoma by supplementing Liver and spleen with TACE and 3-DCRT can significantly improve the clinical symptoms, improve the quality of life of patients, improve the biochemical indicators and immune function,and secure.